Quince Acquires Orphai, Secures $115M Upfront in $187M Financing

Quince Therapeutics acquired Orphai Therapeutics, a clinical-stage biotechnology company, bringing the lead program LAM-001 into its pipeline. Concurrent with the acquisition, Quince secured up to $187 million in private placement financing, including $115 million upfront, to advance LAM-001. The financing, combined with existing cash, is expected to fund operations through the end of 2028 and support multiple clinical milestones, including Phase 2b PH-ILD data in Q1 2028 and Phase 2 BOS data in Q1 2027. Promising Phase 2a data for LAM-001 in PH-ILD were also announced, showing clinically meaningful improvements.